Merck Inc announced that a phase II study of MK 7655 (relebactam), in combination with imipenem and cilastatin, in complicated...
A Phase III, randomised, double-blind, active comparator-controlled clinical trial to estimate the efficacy and safety of imipenem/cilastatin/relebactam versus colistimethate sodium...
Merck has announced that a pivotal Phase III study of relebactam, the company�s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin,...
Based in part on the results of its Phase II study, Merck is planning to initiate two pivotal Phase III...